If someone over 50 breaks a wrist after falling from standing height, has only the wrist been injured?

Australian osteoporosis guidance treats that fracture as clinical information about the whole skeleton. A break caused by a force that would not usually fracture healthy bone is called a minimal-trauma or fragility fracture. In a person over 50, it supports a presumptive diagnosis of osteoporosis and should trigger assessment for the causes of weak bone, the chance of another fall and the risk of another fracture.

That response often does not happen. The Australian Commission on Safety and Quality in Health Care reported in July 2026 that up to 80% of people remain undiagnosed and untreated even after presenting with a fragility fracture. Among Australians hospitalised with a hip fracture, only 35% leave hospital taking a bone-protection medicine.

Why the fracture can be more informative than one scan

Bone mineral density is commonly measured with dual-energy X-ray absorptiometry, usually shortened to DXA. The result includes a T-score, which compares bone density with that of a young adult reference population. A T-score of −2.5 or lower is one way osteoporosis can be diagnosed in postmenopausal women and men over 50.

It is not the only way. Bone strength also reflects structure, turnover, age, previous fractures, medicines and disease. The force applied to the skeleton changes what a fracture means. A bone-density result can sit above the osteoporosis threshold while the person’s combined fracture risk is still high.

The 2024 RACGP and Healthy Bones Australia guideline therefore says that adults over 50 who sustain a fracture after minimal trauma should be considered to have a presumptive diagnosis of osteoporosis. A hip or vertebral fracture can establish the clinical diagnosis without waiting for DXA, although a scan can still help with a baseline measurement, risk stratification and later monitoring.

Not every broken bone after 50 is an osteoporotic fracture. A high-speed collision, a tumour involving bone or an unusual fracture pattern requires a different explanation. The mechanism and site need clinical review. The key distinction is that a low-trauma fracture should not be dismissed as bad luck before bone health has been considered.

A trial measured what happened after hip fracture

The HORIZON Recurrent Fracture Trial tested whether treatment after a low-trauma hip fracture could prevent another clinical fracture. It enrolled 2,127 women and men with a mean age of 74.5 after surgical repair of a hip fracture. Participants were unable or unwilling to take an oral bisphosphonate. Within 90 days of surgery, they were randomly assigned to yearly intravenous zoledronic acid or placebo; both groups received calcium and vitamin D. Median follow-up was 1.9 years.

A new clinical fracture occurred in 8.6% of the zoledronic-acid group and 13.9% of the placebo group. The hazard ratio was 0.65, with a 95% confidence interval from 0.50 to 0.84. The absolute difference was 5.3 percentage points—about one fewer person with a new clinical fracture for every 19 treated over the trial period, using the reported two-year rates.

New clinical vertebral fractures occurred in 1.7% versus 3.8%, and non-vertebral fractures in 7.6% versus 10.7%. Repeat hip fracture was numerically lower, 2.0% versus 3.5%, but that comparison was not statistically conclusive. Death was also lower, 9.6% versus 13.3%, although mortality was a secondary outcome and the reason for the difference remains uncertain.

This was a treatment trial in selected older adults after hip-fracture surgery. It does not show that every person with a wrist, rib or vertebral fracture should receive zoledronic acid. It does show that the period after a major fragility fracture is not too late for prevention.

Treatment choice still needs clinical work

Zoledronic acid caused more short-lived fever, muscle pain and bone or musculoskeletal pain than placebo. Serious adverse events were similar between groups. Renal and cardiovascular event rates were also similar, no cases of osteonecrosis of the jaw were reported, and delayed healing was not increased. Three people receiving zoledronic acid developed adjudicated hypocalcaemia, compared with none receiving placebo.

The trial team added vitamin D loading because deficiency was common. That detail captures a wider point: bone-protection treatment follows assessment. Kidney function, calcium and vitamin D status, dental health, previous treatment, other medicines and the level of imminent fracture risk can all change which option is suitable and when it should begin.

Fracture liaison services close the handover gap

A fracture may be repaired in an emergency department or orthopaedic service, while osteoporosis care usually continues in general practice, geriatrics, endocrinology or rheumatology. Without clear ownership, the injury heals and the underlying risk receives no follow-up.

Fracture liaison services are designed to prevent that loss between services. A coordinator identifies eligible patients, arranges bone and falls assessment, supports treatment or referral, and checks that the plan continues after discharge.

A 2024 systematic review examined 37 studies involving 115,381 adults aged 50 or older after a fragility fracture. At two years or longer, 13 pooled studies with 33,811 participants found fewer secondary fractures with fracture liaison care: risk ratio 0.68, with a 95% confidence interval from 0.55 to 0.83. At three to 12 months, the pooled result was neutral.

Most included studies were observational, programs differed, and follow-up methods were often poorly reported. The analysis supports coordinated care over time; it cannot supply one universal absolute benefit for every service. Australia’s Hip Fracture Clinical Care Standard nevertheless makes the pathway explicit: before discharge, patients should receive a falls and bone-health assessment and management plan, with secondary-prevention referral and bone-protection treatment where indicated.

The question to ask after the cast or operation

A post-fracture review can examine how the injury happened, previous fractures, height loss or back pain that could indicate an unrecognised vertebral fracture, medicines that affect bone or balance, relevant blood tests, nutrition, kidney function, falls, vision, strength and the home environment. DXA may add useful information, but it should not become a reason to postpone the rest of the assessment.

The memorable question is simple: “Was this a low-trauma fracture, and who owns the plan to reduce the chance of another?” Repairing the first bone addresses the immediate injury. Recognising what the fracture says about future risk is the beginning of secondary prevention.

Sources

Evidence note: This Insight is general education, not individual medical advice. It does not diagnose osteoporosis or recommend a particular scan, medicine, supplement or exercise plan. A qualified clinician should assess the fracture mechanism, future risk, possible underlying causes and treatment options in context.